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Phenytoin has become one of the most widely-used anti-epileptic drugs (AED)
over the last several decades. The pharmacokinetics of phenytoin is nonlinear, and
the drug has a narrow therapeutic range.1 Small changes of dosage may greatly
alter serum phenytoin levels and can lead to an overdose. Dosage changes must
be carefully monitored as the therapeutic range is approached.2 The results of
several studies have suggested that increases in the unbound fraction of drugs that
are highly bound to serum proteins increases the incidence of therapy-related
toxic effects.3,4 Only free, unbound phenytoin molecules can penetrate the blood-
brain barrier and exert pharmacological effects;5 therefore, these molecules are the
ones responsible for the therapeutic and toxic effects. Measurement of the
concentration of the free form of phenytoin is considered to better reflect clinical
status than total concentration.6 Total concentration is easily measured, and then
free concentration is predicted using that value. The therapeutic range of the free
phenytoin serum concentration is about 10% of that of the total phenytoin serum
concentration and varies from 3.3 to 9.6 µmol/L (0.83 - 2.27 mg/L).7,8 Only a few
specialized laboratories offer to analyze the free phenytoin concentration because
it is a more expensive and time-consuming test.
Phenytoin is primarily bound to serum albumin, although a smaller but
significant portion is bound to α1-acid-glycoprotein (AAG).9 The concentration
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Purpose: The pharmacokinetics of phenytoin is complicated by genetic and environmental differences. It is,
therefore, important to monitor the serum concentrations in patients who receive phenytoin. Because most of the
phenytoin in serum is bound to proteins, the level of serum albumin influences the amount of free phenytoin.
Materials and Methods: We compared the measured and calculated free phenytoin levels in epileptic patients who
were taking phenytoin monotherapy, using the Sheiner-Tozer equation. A total of 49 patients (30 men and 19
women; age range, 15 - 87 years) were included in the study and their trough serum phenytoin and albumin
concentrations were analyzed. Results: The linear correlation between free and total phenytoin concentrations was
moderate (r = 0.822, p < 0.001). The mean difference between measured and calculated free phenytoin was large
(0.65 ± 0.88 µg/mL; 95% confidence interval (CI), -1.11 to 2.41). After dividing the patients into groups by
albumin concentration, hypoalbuminemic patients (< 3.5 g/dL) more often had a greater percent difference (≥ 20%)
than observed in the normoalbuminemic (≥ 3.5 g/dL) group. Conclusion: In hypoalbuminemic patients, the
measurement of free phenytoin level is necessary to properly evaluate the phenytoin level than that calculated from
total phenytoin level.
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INTRODUCTION
of albumin in serum is decreased with inflammation,
chronic liver disease, or malnutrition. The presence of
hypoalbuminemia is known to reduce the protein binding of
phenytoin in plasma,8,10 and both the ratio of free/total
phenytoin concentration and the total phenytoin concen-
tration may be altered. Therefore, it is difficult to accurately
estimate the free phenytoin concentration from the total
concentration. 
Sheiner and Tozer proposed a correction formula based
on serum albumin concentrations, and this is often used to
estimate the free fraction of phenytoin using total concen-
tration measurements.11 This study compared the relation-
ship between measured and calculated free phenytoin
derived from the Sheiner-Tozer equation in order to assess
the usefulness of monitoring the free concentration of
phenytoin in epileptic patients.
Subjects
Total and free phenytoin concentrations were measured in
49 epileptic patients (30 males and 19 females) receiving
oral phenytoin for more than 7 days. We excluded patients
who took other drugs that influence the metabolism of
phenytoin such as other anti-epileptic drug, heparin, war-
farin, aspirin, fatty acids, or tolbutamide. We also excluded
subjects with pregnancy, end-stage renal disease or blood
transfusion therapy. We collected trough levels of total and
free phenytoin and serum albumin concentrations simulta-
neously. 
Serum phenytoin level analysis
The serum total phenytoin level was analyzed using fluo-
rescence polarization immunoassay (FPIA) technology
(COBAS INTEGRA 800; Roche Diagnostics, Basel,
Switzerland). Specimens were tested within 2 hours of
collection. Free phenytoin levels were also analyzed using
the same technology (TDx / TDxFLx; Abbott Laboratories,
Abbott Park, IL, USA). Samples were ultrafiltered imme-
diately after collection by centrifugation at 1000 - 2000×g
for 15 - 20 minutes at 25 ± 3˚C with an assembled ultrafil-
tration device. 
Corrected total phenytoin
Total phenytoin results were corrected for albumin con-
centration using the Sheiner-Tozer equation.
The relationship between the plasma drug and protein
concentrations can be expressed as follows, and this
equation can be used to estimate the degree to which an
altered plasma protein concentration will affect the desired
therapeutic drug concentration. Cp’ represents the patient’s
plasma drug concentration and P’ is the plasma protein con-
centration. Cpnormal binding is the plasma drug concentration
that would be expected if the patient’s plasma protein
concentration were normal (PNL).
Cp’/Cpnormal binding =  (1-α)[P’/PNL] + α (Equation 1)
Placing the corresponding values for a normal plasma
albumin results as follows: 
Corrected total phenytoin = [total phenytoin (µg/mL)] /
{[albumin (g/dL) / 4.4] × 0.9 + 0.1} (Equation 2)
Based on the corrected concentration of total phenytoin,
the calculated free phenytoin concentration can be obta-
ined by multiplying by 0.1.12
Statistical analysis
The Pearson product-moment correlation coefficient (r)
was used to measure linear association between variables.
The mean difference between actual free phenytoin and
calculated free phenytoin by the Sheiner-Tozer equation
was determined by regression analysis with 95% confi-
dence intervals for the mean difference defined as 2D. The
F test, in the analysis of variance, was used to compare the
ratio of free to total phenytoin concentrations between three
different serum albumin intervals with a post hoc Bonfer-
roni adjustment for multiple group comparisons. All stati-
stical analyses were performed with the assistance of com-
puter software (SPSS version 11.5). Two-tailed values of p
< 0.05 were considered statistically significant with Bon-
ferroni adjustment as appropriate.
The mean age of the patients was 52.7 ± 17.8 years (range,
15 to 87 years), and the mean weight was 59.3 ± 13.1 kg.
The mean serum albumin concentration was 3.3 ± 0.8
g/dL, (range 1.3 to 4.9 g/dL). Hypoalbuminemia (< 3.5
g/dL) was present in 34 patients and normoalbuminemia
(≥ 3.5 g/dL) in 15 patients. 
The linear correlation between free and total phenytoin
concentrations was moderate (Pearson r = 0.822, p < 0.001)
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Fig. 1. Distribution of free and total serum phenytoin concentrations.
(Fig. 1). The coefficient of determination between free and
total phenytoin concentrations (R2 = 0.68) indicated that
68% of the variation in free levels is explained by total
phenytoin concentration (p < 0.001). 
After correction using the Sheiner-Tozer equation, the
correlation between free and total phenytoin concentration
was not improved (Pearson r = 0.762, R2 = 0.58), and the
mean difference between measured and calculated free
phenytoin (one tenth of the Sheiner-Tozer corrected value)
remained high (0.65 ± 0.88 µg/mL; 95% confidence
interval, -1.11 to 2.41). There was also substantial scatter
in this relationship (Fig. 2).
A negative correlation was observed between albumin
and free phenytoin fraction, demonstrating that lower serum
albumin levels were associated with higher free fractions.
Interestingly, the binding ratio observed with hypoalbumi-
nemia was elevated to 0.25 (25.3% free phenytoin) (Fig. 3).
We also compared the percent difference between the
calculated and measured free phenytoin levels of the hypoal-
buminemic (< 3.5 g/dL) and normoalbuminemic (≥ 3.5
g/dL) groups. By cross tabulation analysis, hypoalbu-
minemic patients more often had a greater percent differ-
ence (≥ 20%) than observed in the normoalbuminemic
group (p = 0.029) (Table 1).
There has been debate about whether the measurement of
free serum phenytoin is necessary to ensure that therapeutic
levels of the phenytoin are not exceeded in epileptic patients.
A number of previous studies have drawn attention to the
fact that the use of total phenytoin concentrations in certain
patient groups may misguide therapy. Dutkiewicz et al.13
showed that in hypercholesterolemia and mixed hyperlipi-
demia, the blood level of free phenytoin was elevated, with
the degree of change being dependent on the type of hyper-
lipidemia. The effect was shown to be related to displace-
ment of the drug from albumin by fatty acids.14 Doucet et
al.15 found differences in the protein binding of phenytoin
in diabetics and concluded that the difference in protein
binding between diabetic and control sera was related to
the glucose-independent modification of albumin. In
patients with renal disease and in some with hepatic
disease, there may be not only a low albumin concentra-
tion but also a decrease in protein binding.16,17
It is generally recognized that only free phenytoin
molecules are pharmacologically active. The development
of side effects has been reported to correlate better with free
phenytoin concentrations rather than with total phenytoin
concentrations.18,19 Banh et al. showed that most patients
who developed phenytoin toxicity had a normal or low
total phenytoin concentration but an elevated free serum
phenytoin concentration.18
Our study also showed that free phenytoin levels calcu-
lated using total phenytoin concentrations were unsuitable
for directing therapy in hypoalbuminemic patients, and
that free concentrations should be routinely monitored. 
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Table 1. Cross Tabulation of Percent Difference and Albumin Level, Demonstrating a  Much Greater Percent 
Difference in Hypoalbuminemic Patients (p = 0.029)
Percent difference ≥ 20% Percent difference < 20% Total
Albumin < 3.5 29 5 34
Albumin ≥ 3.5 8 7 15
Total 37 12 49
Albumin (g/dL)M
ea
su
re
d-
es
tim
at
ed
 fr
ee
 p
he
ny
to
in
 ( 
   g
/d
L)
2 2.5 3 3.5 4 4.5 5 5.51.5
-1
-0.75
-0.5
-0.25
0.25
0
0.5
0.75
1.25
1.75
2.25
2.75
3.25
1
1.5
2
2.5
3
3.5
Fig. 2. The mean difference (solid line) between actual and calculated free
phenytoin. One tenth of the Sheiner-Tozer corrected value was 0.65 ± 0.88
µg/mL; 95% confidence interval, -1.11 to 2.41, and considerable scatter is
observed in this relationship. 
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Fig. 3. Phenytoin binding ratio and serum albumin concentration in patients. The
binding ratio of free to total phenytoin is greater (25.3% free phenytoin) in
patients with hypoalbuminemia (less than 3.5 g/dL) (p =  0.002).
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Ji-Man Hong, et al.
Yonsei Med J   http://www.eymj.org    Volume 50   Number 4   August 2009520
Serum albumin concentrations < 3.5 g/dL have previo-
usly been shown to affect phenytoin binding ratios and to
contribute to phenytoin intoxication.20 Decreased protein
binding leads to an increase in the free fraction of the drug.
The free fraction of the drug is the portion that is available
for metabolism and clearance by the liver. In essence,
increzasing the free fraction of the drug increases the sub-
strate present to the liver for metabolism, thereby poten-
tially increasing the metabolism of the drug. This may
result in a decrease in the total concentration of the drug
while the free concentration remains constant. In this setting,
patients are at particular risk for toxicity if clinicians increase
doses in order to achieve therapeutic total concentrations.21
In our patients, we found that 15 patients (31%) had free
concentrations above the therapeutic level (> 2 µg/mL)
despite total concentrations within the therapeutic range.
Among these 15 patients, 10 patients had severe hypoal-
buminemia.
The Sheiner-Tozer equation was recently used in a study
to calculate free concentration in critically ill neurosurgical
patients.12 The authors found that, in this uniform patient
population, the equation provided an unbiased and precise
means of estimating free concentration if direct measure-
ment was unavailable or impractical. The authors stated
that the reason for the precision in their patient population,
and hence the reason why their results differed from those
of previous reports, was that their patients did not have
clinical conditions that alter protein binding.22
Considering our results, methods of calculating the free
concentration of phenytoin in patients with hypoalbumi-
nemia should be used with caution.
1. Nuwer MR, Browne TR, Dodson WE, Dreifuss FE, Engel J Jr,
Leppik IE, et al. Generic substitutions for antiepileptic drugs.
Neurology 1990;40:1647-51.
2. Richens A, Dunlop A. Serum-phenytoin levels in management of
epilepsy. Lancet 1975;2:247-8.
3. Kilpatrick CJ, Wanwimolruk S, Wing LM. Plasma concentra-
tions of unbound phenytoin in the management of epilepsy. Br J
Clin Pharmacol 1984;17:539-46.
4. Mackichan JJ. Pharmacokinetic consequences of drug displace-
ment from blood and tissue proteins. Clin Pharmacokinet 1984;9
Suppl 1:32-41.
5. Soldin SJ. Free drug measurements. When and why? An overview.
Arch Pathol Lab Med 1999;123:822-3.
6. Perucca E. Free level monitoring of antiepileptic drugs. Clinical
usefulness and case studies. Clin Pharmacokinet 1984;9 Suppl
1:71-8.
7. Bryson SM, Al-Lanqawi Y, Kelman AW, Whiting B. Compa-
rison of a Bayesian forecasting technique with a new method for
estimating phenytoin dose requirements. Ther Drug Monit 1988;
10:80-4.
8. Levine M, Chang T. Therapeutic drug monitoring of phenytoin.
Rationale and current status. Clin Pharmacokinet 1990;19:341-58.
9. Bailey DN, Briggs JR. The binding of selected therapeutic drugs
to human serum alpha-1 acid glycoprotein and to human serum
albumin in vitro. Ther Drug Monit 2004;26:40-3.
10. Fedler C, Stewart MJ. Plasma total phenytoin: a possibly mis-
leading test in developing countries. Ther Drug Monit 1999;21:
155-60.
11. Sheiner LB, Tozer TN. Clinical pharmacokinetics: the use of
plasma concentrations of drugs. In: Melmon KL, Morelli HF,
editors. Clinical Pharmacology: Basic Principles in Therapeutics.
New York: Macmillan; 1978. p.71-109.
12. Mlynarek ME, Peterson EL, Zarowitz BJ. Predicting unbound
phenytoin concentrations in the critically ill neurosurgical patient.
Ann Pharmacother 1996;30:219-23.
13. Dutkiewicz G, Wójcicki J, Gawron´ska-Szklarz B. [The influence
of hyperlipidemia on pharmacokinetics of free phenytoin.] Neurol
Neurochir Pol 1995;29:203-11.
14. Dasgupta A, Crossey MJ. Elevated free fatty acid concentrations
in lipemic sera reduce protein binding of valproic acid signifi-
cantly more than phenytoin. Am J Med Sci 1997;313:75-9.
15. Doucet J, Fresel J, Hue G, Moore N. Protein binding of digitoxin,
valproate and phenytoin in sera from diabetics. Eur J Clin Phar-
macol 1993;45:577-9.
16. Hooper WD, Bochner F, Eadie MJ, Tyrer JH. Plasma protein
binding of diphenylhydantoin. Effects of sex hormones, renal and
hepatic disease. Clin Pharmacol Ther 1974;15:276-82.
17. Odar-Cederlöf I, Borga O. Kinetics of diphenylhydantoin in urae-
mic patients: consequences of decreased plasma protein binding.
Eur J Clin Pharmacol 1974;7:31-7.
18. Banh HL, Burton ME, Sperling MR. Interpatient and intrapatient
variability in phenytoin protein binding. Ther Drug Monit 2002;
24:379-85.
19. Peterson GM, Khoo BH, von Witt RJ. Clinical response in epilepsy
in relation to total and free serum levels of phenytoin. Ther Drug
Monit 1991;13:415-9.
20. Lindow J, Wijdicks EF. Phenytoin toxicity associated with hypo-
albuminemia in critically ill patients. Chest 1994;105:602-4.
21. Wolf GK, McClain CD, Zurakowski D, Dodson B, McManus
ML. Total phenytoin concentrations do not accurately predict free
phenytoin concentrations in critically ill children. Pediatr Crit
Care Med 2006;7:434-9.
22. Monaghan MS, Marx MA, Olsen KM, Turner PD, Bergman KL.
Correlation and prediction of phenytoin protein binding using
standard laboratory parameters in patients after renal trans-
plantation. Ther Drug Monit 2001;23:263-7.
REFERENCES
˚
